Related Experiment Video
Updated: Jan 13, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.7K
Carbon Ion Radiotherapy for Retroperitoneal Sarcoma: A Single-Institution Study
Reiko Imai1, Tsukasa Yonemoto2, Nobuhito Araki3
1QST Hospital, National Institute of Quantum Science and Technology,4-9-1, Anagawa, Inage, Chiba Shi 263-8555, Chiba, Japan.
Cancers
|October 29, 2025
Summary
Carbon ion radiotherapy (CIRT) offers a definitive treatment for unresectable retroperitoneal sarcoma (RPS). This study shows promising survival and local control rates, with manageable late adverse events in patients with RPS.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Surgery is the primary treatment for retroperitoneal sarcoma (RPS).
- Definitive treatment strategies for unresectable RPS or those with insufficient margins are unclear.
- Carbon ion radiotherapy (CIRT) is an option for unresectable RPS.
Purpose of the Study:
- To evaluate the effectiveness of CIRT in patients with unresectable RPS.
- To assess survival rates, local control, and recurrence-free survival after CIRT.
- To determine the incidence of late adverse events following CIRT.
Main Methods:
- Retrospective analysis of 76 patients with unresectable RPS treated with CIRT.
- Standardized CIRT protocol: 70.4 Gy in 16 fractions over 4 weeks, with respiratory gating and spot scanning.
- Prognosis confirmed up to 2022 for 95% of patients.
Main Results:
- 3- and 5-year overall survival rates of 68.3% and 49.4%; median overall survival of 58.1 months.
- 3- and 5-year local control rates of 79.0% and 72.0%.
- Grade 3 or higher late adverse events occurred in 5.2% of patients.
Conclusions:
- CIRT is a definitive treatment option for unresectable RPS.
- CIRT demonstrates significant efficacy in local control and survival for RPS.
- Multicenter studies are recommended to validate CIRT effectiveness in larger cohorts.
